title: Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF).
abstract: Hydroxymethylacylfulvene (HMAF, MGI 114) is a novel antitumor drug and a potent pro-apoptotic agent that has the potential to alkylate cellular nucleophiles. The objective of these studies was to characterize drug uptake and cellular targets for drug binding in human leukemia CEM cells. The uptake of [14C]HMAF had two components: a rapid phase (0-10 min) and a slow phase. At 10 microM drug (37 degrees), the rapid and slower phase amounted to 0.86 and 0.13 pmol/min/10(6)cells, respectively. HMAF uptake was inhibited 82% by low temperature (4 degrees) at 4 hr. Cell-associated HMAF localized to nuclear (50%), cytoplasmic (37%), and membrane fractions (10%). Continued drug uptake appeared to be driven by covalent binding to cellular macromolecules. Approximately 1/4 and 2/3 of cell-associated HMAF formed covalent adducts after 10 min and 4 hr, respectively, as found by perchloric acid precipitation. Drug adducts were not readily reversible; 77% of the covalently bound radiolabel was retained by the cells 20 hr after drug treatment. Combinations of DNase, RNase, and proteinase K with perchloric acid precipitation showed that approximately 60, 30, and 10% of the covalently bound drug was associated with the protein, DNA, and RNA fractions, respectively. Incubation of 100 microM [14C]HMAF (24 hr) with purified DNA, serum albumin, thioredoxin, and thioredoxin reductase resulted in 6, 22, 14, and 11 pmol [14C]HMAF/microg DNA or protein, respectively. Results indicate that multiple targets for HMAF binding may contribute to the pro-apoptotic and antiproliferative action of the drug.
authors.affiliation: Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, TX 78245-3217, USA.
authors.forename: M C
authors.initials: MC
authors.lastname: Herzig
authors.forename: B
authors.initials: B
authors.lastname: Arnett
authors.forename: J R
authors.initials: JR
authors.lastname: MacDonald
authors.forename: J M
authors.initials: JM
authors.lastname: Woynarowski
mesh_terms: D000970:Antineoplastic Agents / Q000378:metabolism* / Q000494:pharmacology; D002250:Carbon Radioisotopes; D004273:DNA, Neoplasm / Q000187:drug effects / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D006801:Humans; D046911:Macromolecular Substances; D012710:Serum Albumin, Bovine / Q000378:metabolism; D012717:Sesquiterpenes / Q000378:metabolism* / Q000494:pharmacology; D013950:Thymus Gland / Q000378:metabolism; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D002250:Carbon Radioisotopes; D004273:DNA, Neoplasm; D046911:Macromolecular Substances; D012717:Sesquiterpenes; D012710:Serum Albumin, Bovine; C102714:irofulven